351 related articles for article (PubMed ID: 33964007)
21. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
22. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
23. Graves'-like orbitopathy in a patient with chronic autoimmune pancreatitis.
Fonte R; Pirali B; Caramia V; Dionisio R; Lodigiani S; Sibilla L; Rotondi M; Chiovato L
Thyroid; 2011 Dec; 21(12):1389-92. PubMed ID: 22066480
[TBL] [Abstract][Full Text] [Related]
24. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
25. Genotype-phenotype correlations in Graves' disease.
Radziszewski M; Kuś A; Bednarczuk T
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101745. PubMed ID: 36828713
[TBL] [Abstract][Full Text] [Related]
26. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
[TBL] [Abstract][Full Text] [Related]
27. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
28. Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report.
Rubinstein TJ
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e221-e223. PubMed ID: 34570048
[TBL] [Abstract][Full Text] [Related]
29. [Graves' orbitopathy: diagnosis, epidemiology and treatments].
Lun AY; Le Bras M; Scharbarg E; Morcel P; Hadjadj S; Lebranchu P; Drui D
Rev Med Interne; 2022 Apr; 43(4):242-251. PubMed ID: 35221112
[TBL] [Abstract][Full Text] [Related]
30. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.
Antonelli A; Fallahi P; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Gonnella D; Giusti C; Virili C; Centanni M; Shoenfeld Y; Ferrari SM
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101388. PubMed ID: 32059832
[TBL] [Abstract][Full Text] [Related]
31. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
32. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
[TBL] [Abstract][Full Text] [Related]
33. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease.
Mourits MP
Orbit; 2008; 27(6):399-400. PubMed ID: 19085291
[No Abstract] [Full Text] [Related]
34. COVID-19 vaccination and thyroiditis.
Şendur SN; Oğuz SH; Ünlütürk U
Best Pract Res Clin Endocrinol Metab; 2023 Jul; 37(4):101759. PubMed ID: 36933997
[TBL] [Abstract][Full Text] [Related]
35. Graves' ophthalmopathy. A clinical and immunologic review.
Sergott RC; Glaser JS
Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
[TBL] [Abstract][Full Text] [Related]
36. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
[TBL] [Abstract][Full Text] [Related]
37. The role of genetics in Graves' disease and thyroid orbitopathy.
Kim N; Hatton MP
Semin Ophthalmol; 2008; 23(1):67-72. PubMed ID: 18214794
[TBL] [Abstract][Full Text] [Related]
38. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
[TBL] [Abstract][Full Text] [Related]
39. Graves' ophthalmopathy and dermopathy. Preface.
Wiersinga WM
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):227. PubMed ID: 22632360
[No Abstract] [Full Text] [Related]
40. Constellation of autoimmune manifestations in a patient with Graves' disease.
Dutta A; Jain N; Bhansali A
Postgrad Med J; 2018 Sep; 94(1115):538. PubMed ID: 29728450
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
